Vitamin D deficiency.
Conditions
Interventions
Intervention 1: First intervention group: 600 mg of N-acetyl cysteine +1000 units of vitamin D ??daily for 8 weeks. Intervention 2: Second intervention group: 5000 units of vitamin D daily for 8 weeks
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: Elderly people with a body mass index of 25-32 kg/m2 Serum vitamin D deficiency (less than 30 ng/mL) Age over 65 years old No chronic and acute inflammatory and infectious diseases Not suffering from diabetes and thyroid diseases Not suffering from Alzheimer's and dementia Not receiving alcohol and smoking Not receiving medication or a disorder that affects vitamin D metabolism (anticonvulsant drugs, antituberculosis drugs, glucocorticoids, HIV drugs) Not receiving vitamin D and N-acetyl cysteine and antioxidant supplements in the last three months Non-participation in other clinical trial studies at the same time as the present study
Exclusion criteria
Exclusion criteria: Hypercalcemia (more than 2.6 mmol/L) Dysparathyroidism, kidney failure and stones, and long-term treatment with bisphosphonates and corticosteroids. Consumption of less than 90% of prescribed supplements Unwillingness to cooperate during the intervention
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in p21 gene expression. Timepoint: Before and after intervention. Method of measurement: Quantitative Real-time Polymerase chain reaction.;Changes in p16 gene expression. Timepoint: Before and after intervention. Method of measurement: Quantitative Real-time Polymerase chain reaction.;Changes in TNFa gene expression. Timepoint: Before and after intervention. Method of measurement: Quantitative Real-time Polymerase chain reaction.;Changes in IL-6 gene expression. Timepoint: Before and after intervention. Method of measurement: Quantitative Real-time Polymerase chain reaction.;Changes in beta-galactosidase activity. Timepoint: Before and after intervention. Method of measurement: x-gal staining.;Serum IL-6. Timepoint: Before and after intervention. Method of measurement: ELISA KIT.;Serum TNFa. Timepoint: Before and after intervention. Method of measurement: ELISA KIT. | — |
Secondary
| Measure | Time frame |
|---|---|
| NLR: Neutrophil to Lymphocyte Ratio. Timepoint: Before and after intervention. Method of measurement: Calculation based on complete blood count with Differential test.;C-Reactive Protein. Timepoint: Before and after intervention. Method of measurement: Elisa kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamira Rastgoo
Shahid Beheshti University of Medical Sciences
Outcome results
None listed